Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Objective We sought to investigate the safety and efficacy of pegylated Interferon (PEG-IFN) and ribavirin for chronic hepatitis C (HCV) following renal transplantation.
Methods Ten adult living-related renal transplant recipients of >12-month duration, infected with HCV, and with stable renal graft function were recruited. All patients were administered with PEG-IFN-α 2b 50 μg/week, plus ribovirin 400600 mg/day.HCV viral load was reexamined monthly. Consolidation therapy lasted for 3-9 months after initial remission of HCV-RNA. Viral response, adverse effects and changes in hemogram, alanine aminotransferase, and serum creatinine were also monitored.
Results The duration of treatment for 10 patients was 4-20 months. Sustained virologic response (SVR) occurred in 7 patients with no relapse during 6-month follow-up period after the cessation of the treatment. Two patients, with rapid virologic response, had a virologic relapse after completing their 3-month consolidation therapy. One patient maintained no obvious virologic response during 8 months of treatment. Renal function was kept in normal range in all patients and no one experienced a rejection episode during or after PEG-IFN-α 2b therapy. The major adverse reactions included influenza-like syndrome (fever, muscle soreness, anorexia et al.), transient bone marrow suppression and anemia. All of the adverse reactions were transient and tolerable, and no discontinuation of PEG-IFN-α 2b therapy was required in all these patients.
Conclusion For renal transplant recipients with stable renal graft function, treatment with PEG-IFN-α 2b and ribavirin has high efficacy in the treatment of chronic HCV and is not associated with high risk of acute rejection of renal allografts.
To cite this abstract in AMA style:Chen G, Zhu L, Chen S, Wang X, Lin Z. Safety and Efficacy of Pegylated Interferon and Ribavirin for Chronic Hepatitis C Following Renal Transplantation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-pegylated-interferon-and-ribavirin-for-chronic-hepatitis-c-following-renal-transplantation/. Accessed January 17, 2021.
« Back to 2015 American Transplant Congress